Search clinical trials for: three-negative Breast Cancer with germline BRCA-mutated

Total 204133 results

The First Affiliated Hospital with Nanjing Medical...
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast Cancer

TNBC - Triple-Negative Breast Cancer

China
Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations

Breast Cancer Metastatic

China
Institut Claudius Regaud
Artios Pharma Ltd

Recruiting

Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer. (REPARP)

Breast Cancer

France
Seoul National University Hospital

Recruiting

Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency

Advanced Breast Cancer

Korea, Republic of
Senhwa Biosciences, Inc.

Recruiting

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

Advanced Solid Tumor

United States, Canada
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Austrian Breast & Colorectal Cancer Study...

Recruiting

Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation (BRCA-P)

Neoplasms | Breast Cancer | Breast Neoplasms | Breast Diseases | Breast Carcinoma | BRCA1 Mutation

United States
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions

United States
University of Malaya
National University Hospital, Singapore; Merck Sharp & Dohme LLC; Cancer Research...

Recruiting

Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients With APOBEC3B Mutation

HER2-Negative Breast Cancer

Singapore, Malaysia
National Cancer Institute (NCI)

Recruiting

Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer

Breast Carcinoma | Neuropathy

United States
National Cancer Institute (NCI)

Recruiting

Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer

Breast Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer

Breast Carcinoma

United States
Johns Hopkins University
National Cancer Institute (NCI); National Institutes of Health (NIH); ChiRhoClin...

Recruiting

The Cancer of the Pancreas Screening-5 CAPS5)Study (CAPS5)

Lynch Syndrome | Pancreas Cancer | Gene Mutation | Peutz-Jeghers Syndrome (PJS) | Germline Mutation Carrier

United States
AstraZeneca
Merck Sharp & Dohme LLC; NRG Oncology; Breast International Group; Myriad Genetic... and other collaborators

Active, not recruiting

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer (OlympiA)

Breast Cancer

United States, Austria, Italy, Spain, Sweden, United Kingdom, Belgium, Poland, France, Switzerland, Canada, Germany, Korea, Republic of, Netherlands, Japan, China, Taiwan, Australia, Argentina, Israel, Hungary, Portugal, Iceland, Puerto...
Institut fuer Frauengesundheit
Merck Sharp & Dohme LLC

Active, not recruiting

Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO (COMPRENDO)

Breast Cancer | Malignant Neoplasm of Breast

Germany
AstraZeneca
Merck Sharp & Dohme LLC; Myriad Genetic Laboratories, Inc.

Active, not recruiting

Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (OlympiAD)

Breast Cancer Metastatic | BRCA 1 Gene Mutation | BRCA 2 Gene Mutation

Italy, Spain, United States, Czechia, Romania, France, Korea, Republic of, United Kingdom, Hungary, Japan, Peru, Poland, Russian Federation, Turkey, China, Taiwan, Bulgaria, Switzerland, Mexico
King Hussein Cancer Center

Active, not recruiting

Universal Genetic Testing Versus Guidelines-Directed Testing for Germline Pathogenic Variants Among Non-Western Patients With Breast Cancer

Breast Cancer

Jordan
AstraZeneca

Active, not recruiting

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

Metastatic Triple Negative Breast Cancer

United States, Belgium, Italy, Spain, United Kingdom, Canada, Czechia, Poland, France, Korea, Republic of, Germany, Taiwan, Portugal, Netherlands, Ireland
UNICANCER
ARCAGY/ GINECO GROUP; SOLTI Breast Cancer Research Group

Active, not recruiting

Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients. (DOLAF)

ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer | a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status

France
pharmaand GmbH

Terminated

A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes (LODESTAR)

Solid Tumor

United States
Hellenic Cooperative Oncology Group
Hellenic Society of Medical Oncology

Active, not recruiting

Detection of Germline and Somatic Pathogenic Variants in Patients With de Novo Metastatic Breast Cancer

Metastatic Breast Cancer

Greece
Peking University People's Hospital
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Enrolling by invitation

Neoadjuvant Fluzoparib Combined With Camrelizumab in Germline BRCA-mutated HER2-negative Breast Cancer

Germline BRCA-mutated HER2-negative Breast Cancer

China
Pfizer

Terminated

Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Early Breast Cancer

United States
Washington University School of Medicine
Pfizer; Rising Tide Foundation

Terminated

Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer (PALTAN)

Breast Cancer | Breast Carcinoma | Cancer of Breast

United States
University Hospital, Rouen

Completed

Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in Early Onset Cancers With Sporadic or Hereditary Presentation (PANEL)

Breast Cancer | Colorectal Cancer | Ovarian Cancer | Pediatric Cancers | Multiple Primary Malignant Tumours

France
German Breast Group
AstraZeneca

Completed

Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency (GeparOla)

Breast Cancer | Triple Negative Breast Neoplasms | HRpos Breast Neoplasms | BRCA 1 /2 and / or HRD

Germany
Pamela Munster
QuantumLeap Healthcare Collaborative

Terminated

Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer

Triple Negative Metastatic Breast Cancer | BRCA-mutated Solid Tumor

United States
Lund University

Completed

Written Genetic Counseling and Mutation Analysis of BRCA1 and BRCA2 to Patients With Breast Cancer (BRCAsearch)

Hereditary Breast Cancer

Sweden
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

HER2-positive Breast Cancer

China
Fundacio Clinic Barcelona
University of Padova; Sheba Medical Center; Istituto Oncologico Veneto IRCCS; University... and other collaborators

Not yet recruiting

Diagnostic HER2DX-guided Treatment for patIents wIth Early-stage HER2-positive Breast Cancer (DEFINITIVE)

HER2-positive Breast Cancer | Early-stage Breast Cancer
Breast Cancer Trials, Australia and New Zealand

Not yet recruiting

Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International Validation Experience (PROSPECTIVE)

Breast Cancer | Breast Cancer Female
University of Texas Southwestern Medical Center

Not yet recruiting

Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial

Breast Cancer

United States
Astellas Pharma Global Development, Inc.

Not yet recruiting

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy

Hot Flashes
Angiex, Inc.

Recruiting

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

Cancer | Pancreatic Adenocarcinoma | Triple Negative Breast Cancer | Metastatic Solid Tumor | Advanced Cancer | Pancreas Cancer | Locally Advanced Carcinoma

United States
MediLink Therapeutics (Suzhou) Co., Ltd.

Not yet recruiting

A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC

Locally Advanced or Metastatic Breast Cancer

China
Dana-Farber Cancer Institute
Johns Hopkins University; Translational Breast Cancer Research Consortium

Not yet recruiting

The SAPPHO Study: A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

Breast Cancer | HER2-positive Breast Cancer | Stage IV Breast Cancer | Breast Cancer Female | Breast Cancer Metastatic | Estrogen Receptor-positive Breast Cancer

United States
Roswell Park Cancer Institute

Not yet recruiting

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma | Locally Advanced Unresectable Triple-Negative Breast Carcinoma

United States
Beijing GoBroad Hospital

Not yet recruiting

Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer

Advanced Breast Cancer

China
S.LAB (SOLOWAYS)
Center of New Medical Technologies

Not yet recruiting

Clinical Trial Protocol: Randomized Placebo-Controlled Pilot Study of GcMAF (Soloways TM) in Patients With Metastatic Breast Cancer

Breast Cancer

Russian Federation
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...

Not yet recruiting

CHEmotherapy and Cognitive Deterioration in Patients With Operable Breast Cancer: Impact of Cognitive Rehabilitation (CHEMOFOG) (CHEMOFOG)

Breast Cancer
Jazz Pharmaceuticals

Not yet recruiting

A Phase 3, Randomized, Open-label, Controlled Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

Metastatic HER2-positive Breast Cancer
AstraZeneca

Not yet recruiting

A PROSPECTIVE, MULTI-CENTER, PHASE 4 STUDY TO ASSESS THE SAFETY OF TRASTUZUMAB DERUXTECAN, AN ANTI-HER2-ANTIBODY DRUG CONJUGATE IN INDIAN PATIENTS WITH UNRESECTABLE OR METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE RECEIVED A PRIOR ANTI-HER2-BASED REGIMEN (STRIDE)

BREAST CANCER
Grupo Lusófona
Centro Hospitalar Universitario do Algarve; Universidade Lusófona de Humanidades... and other collaborators

Not yet recruiting

Home-Combo: an Online Home-based Combined Exercise Intervention for Women With Breast Cancer

Breast Cancer | Chemotherapy Effect

Portugal
Lu Hua

Not yet recruiting

Effect of Bupivacaine Liposome Anterior Serratus Deep Block on Chronic Pain After Breast Cancer Surgery: a Randomized Controlled Study

Breast Cancer Patients With Chronic Pain After Surgery

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

The Impact of Socioeconomic Determinants on the Patient Reported Outcomes in Young Breast Cancer Patients After Breast Surgery

Quality of Life | Breast Cancer | Surgery

China
University of Southern California
National Cancer Institute (NCI)

Not yet recruiting

Access to Genetic Testing in Underserved Patients With Cancer

Malignant Solid Neoplasm | Breast Carcinoma | Metastatic Prostate Carcinoma | Ovarian Carcinoma | Triple-Negative Breast Carcinoma | Male Breast Carcinoma | Pancreatic Exocrine Neoplasm | Stage IVB Prostate Cancer American Joint Committee on Cancer v8

United States
Pravin T.P Kaumaya

Not yet recruiting

Vaccine Therapy in Treating Patients With Metastatic Solid Tumors

Metastatic Breast Cancer | HER2-positive Breast Cancer | HER2-positive Gastric Cancer | Metastatic Gastrointestinal Carcinoma | EGFR Overexpression

United States
Institut de cancérologie Strasbourg Europe
Centre de recherche du Centre hospitalier universitaire de Sherbrooke

Recruiting

Prediction of Radiotherapy Efficacy in Patients With Triple-negative Breast Cancer (TNBC-RT2023)

Triple-negative Breast Cancer

France
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Association of Pembrolizumab Infusion Time and Efficacy in Patients With Non-metastatic Triple-negative Breast Cancer (TNBC) Treated With Neoadjuvant Chemotherapy and Immunotherapy (PEMCLOCK)

Non-Metastatic Breast Carcinoma
Universitaire Ziekenhuizen KU Leuven
Belgium Health Care Knowledge Centre

Not yet recruiting

Quilting Sutures After Mastectomy (BE-Quilt)

Breast Cancer

Belgium

Search clinical trials for: three-negative Breast Cancer with germline BRCA-mutated

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bangladesh

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations